Remarkable resilience Johnson & Johnson was founded in 1886. The company has survived and thrived in periods of high tariffs, ...

Johnson & Johnson has said it expects to see a $400 million financial hit from President Trump's tariffs, which will be felt ...

Johnson & Johnson (J&J) has reported its first-quarter 2025 results, showcasing a 2.4% increase in reported sales to $21.9 ...

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

Johnson & Johnson shares dipped slightly today on first-quarter results and an update on the impact of tariffs.

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

American healthcare and consumer products giant Johnson & Johnson hiked its annual guidance after a strong start to the year, with the company beating estimates on both the top and bottom lines.

J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The ...

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on JNJ: Disclaimer & Disclosure Report an Issue Johnson & Johnson NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Reports Q1 revenue $21.9B, consensus $21.57B. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this ...

Johnson & Johnson (J&J) has announced that an injectable version of Rybrevant (amivantamab) has been approved by the European Commission (EC) for two advanced non-small cell lung cancer (NSCLC) ...